SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 92,991.00 |
| Book Value / Share | 20.84 |
| Price / Book | n/a |
| NCAV ($M) | -68,279.00 |
| NCAV / Share | -15.30 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.70 |
| Return on Assets (ROA) | 0.33 |
| Return on Equity (ROE) | 1.05 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.64 |
| Current Ratio | 0.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 139,646.00 |
| Assets | 314,486.00 |
| Liabilities | 207,925.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 232,261.00 |
| Operating Income | 102,574.00 |
| Net Income | 83,683.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 108,908.00 |
| Cash from Investing | -43,892.00 |
| Cash from Financing | -63,158.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock Inc. | 6.90 | 91.15 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 669,922 | 3,142,660 | 21.32 | |
| 706,149 | 3,143,089 | 22.47 | |
| 893,366 | 3,703,606 | 24.12 | |
| 852,793 | 3,798,340 | 22.45 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – AbbVie Inc. | ABT – Abbott Laboratories |
| ADCT – ADC Therapeutics SA | ANRO – Alto Neuroscience, Inc. |
| ANVS – Annovis Bio, Inc. |
Financial data and stock pages provided by
Fintel.io